PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Clinical trials for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: experimental drug AZD4512 enters human trials
Disease control Recruiting nowThis study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: C. Babis Andreadis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
One-Shot gene therapy could simplify cancer treatment
Disease control Recruiting nowThis early-phase trial tests a new injection called IASO207 for people with relapsed or refractory B-cell blood cancers. Unlike current CAR-T therapies that require removing and engineering cells in a lab, IASO207 is designed to create cancer-fighting T cells directly inside the …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study explores immunotherapy for rare cancers in japanese patients
Disease control Recruiting nowThis study is testing the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participan…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New dual-targeting CAR t therapy takes on hard-to-treat lymphoma in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy aims to beat childhood lymphoma
Disease control Recruiting nowThis study is testing whether adding the drug rituximab early and intensively to a strong chemotherapy regimen can improve outcomes for children and teens with aggressive B-cell non-Hodgkin lymphoma. About 87 participants will receive the combination therapy. The goal is to see i…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy aims to stop aggressive lymphoma relapse
Disease control Recruiting nowThis study tests whether adding a drug called golcadomide after standard CAR T-cell therapy can prevent aggressive large B-cell lymphoma from returning in patients at high risk of relapse. About 65 adults will receive golcadomide for 24 weeks starting 5 days after their CAR T-cel…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot takes on tough blood cancers in small safety trial
Disease control Recruiting nowThis early study is testing an injection called IASO208 in 12 adults with certain types of blood cancer that have returned or not improved with standard treatments. The main goal is to see if the treatment is safe and to find the right dose. Researchers will also look at how well…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New 'In-Body' CAR-T therapy takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early study tests a new treatment called KSVCBD for people with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has come back or not responded to other treatments. KSVCBD is a special therapy that works inside the body to help immune cells attack cancer cell…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for young cancer patients: glofitamab trial targets tough lymphoma
Disease control Recruiting nowThis study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether giving two drugs (loncastuximab tesirine and rituximab) before standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has come back or not responded to treatment. About 29 participants will receive this bridging therap…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New CAR T-Cell therapy targets tough lymphomas
Disease control Recruiting nowThis early-phase study tests a new treatment called JV-213 for adults with B-cell lymphoma that has come back or not responded to other treatments. JV-213 uses the patient's own immune cells, modified to attack cancer cells. The main goal is to find the safest dose and monitor si…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug aims to supercharge CAR T-Cells against tough lymphoma
Disease control Recruiting nowThis early-phase trial tests whether adding a drug called NT-I7 after standard CAR T-cell therapy can help the immune cells work better and last longer in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after their CAR T treatmen…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
Disease control Recruiting nowThis study tests a powerful two-step approach for people with a fast-growing type of lymphoma that has not responded to standard treatments. First, patients receive a CAR-T cell therapy (engineered immune cells) followed by a stem cell transplant with high-dose chemotherapy. The …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New CAR-T therapy targets tough childhood cancers
Disease control Recruiting nowThis phase 2 trial is testing a new type of CAR-T cell therapy called MB-CART2019.1 in children and teens (ages 6 months to under 18) with B-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to atta…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Recruiting nowThis phase 2 trial tests whether adding epcoritamab, a bispecific antibody that helps the immune system attack cancer cells, to standard chemotherapy (EPOCH-R) is safe and effective for aggressive B-cell non-Hodgkin lymphoma. About 18 patients with hard-to-treat forms of the dise…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cell therapy CT1182 takes on tough lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowThis study tests a personalized CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. Patients' own immune cells are collected, modified to target cancer cells, and infused back. The trial has two phases: first to find the safest dos…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo aims to boost CAR T-Cell therapy for rare lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard CAR T-cell therapy can improve outcomes for people with relapsed or refractory primary mediastinal B-cell lymphoma. About 35 participants will receive pembrolizumab before and afte…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New injection shows promise for tough lymphoma in early trial
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for tough lymphoma: experimental drug CHO-H01 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Cho Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Virus turns body into cancer-fighting factory for stubborn lymphoma
Disease control Recruiting nowThis early-phase study tests a new approach for patients with B-cell lymphoma that has not responded to standard treatments. A specially designed virus is injected to deliver instructions that turn some of the patient's own immune cells into cancer-killing cells directly inside t…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New antibody drug YK012 takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study is testing a new drug called YK012 in 48 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. YK012 is a bispecific antibody designed to help the body's immune T cells recognize and kill cancer B cells. The main goals are to check the drug's safe…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowThis phase 2 trial tests a new CAR T cell therapy called MB-CART2019.1 in 31 people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, genetically modified to target and k…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Double punch for lymphoma: stem cell transplant plus CAR-T therapy
Disease control Recruiting nowThis study is testing whether giving a special immune cell treatment (CAR-T) right after a stem cell transplant can help people with aggressive B-cell lymphoma that has not responded to standard treatments. The trial will enroll 16 people and measure how many achieve complete rem…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New Dual-Target CAR-T therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new treatment called C-CAR039 (Prizlon-cel) for people with large B-cell lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The goal is to find the saf…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Dual-Target CAR t cells take on tough lymphoma
Disease control Recruiting nowThis early-phase study tests a new type of immunotherapy called CD19x22 CAR T cells for teenagers and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Tuning up CAR t: can a better prep boost lymphoma remission?
Disease control Recruiting nowThis study is for adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to treatment. Researchers want to find the safest and most effective way to prepare the body before giving standard CAR T cell therapy. They are t…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New CAR-T therapy aims to tackle tough lymphoma
Disease control Recruiting nowThis early-stage study is testing a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can a new drug tame CAR-T's dangerous side effects?
Disease control Recruiting nowThis phase 2 trial tests whether emapalumab, a drug that blocks a protein called interferon gamma, can prevent severe cytokine release syndrome (CRS) in patients receiving CAR-T cell therapy for certain types of non-Hodgkin lymphoma. About 28 adults with relapsed or refractory la…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Second CAR t infusion: a new hope for lymphoma patients who relapse?
Disease control Recruiting nowThis early-phase trial is testing whether a second infusion of the CAR T-cell therapy Axi-Cel (called Axi-Cel-2) is safe for people with high-risk large B-cell lymphoma whose cancer came back after standard CAR T treatment. About 20 adults will receive the second infusion and be …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Supercharged immune cells take on tough lymphoma
Disease control Recruiting nowThis early-phase trial tests a new kind of CAR-T cell therapy, called Meta10-19, for people with diffuse large B-cell lymphoma that has come back or not responded to treatment. The cells are 'metabolically armed' to give them extra energy to fight cancer. The study will enroll 18…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 26, 2026 19:06 UTC
-
Eye scanner may predict dangerous brain side effects in cancer treatment
Knowledge-focused Recruiting nowThis study tests whether a non-invasive handheld device that measures pupil size and reactivity can predict neurological side effects in patients receiving CAR-T cell therapy for lymphoma. Researchers will monitor 100 adults before and after treatment to see if pupil changes sign…
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
CAR-T therapy may erase vaccine immunity, new study warns
Knowledge-focused Recruiting nowThis study looks at whether CAR-T cell therapy reduces the body's ability to fight off diseases like measles and mumps that were previously prevented by vaccines. Researchers will measure antibody levels in 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after …
Matched conditions: PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:22 UTC